and independent laboratories shows that one ranitidine 300 mg tablet can contain tens of thousands of nanograms (ng) of NDMA, greatly exceeding the FDA’s daily acceptable intake limit of 96 ng ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer. "GSK today ...

(Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on ...

A Chicago jury failed to reach a verdict Sept. 18 over claims that heartburn drug Zantac causes cancer, Reuters exclusively reported. The case, brought by Illinois resident Ronald Kimbrow ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

Am J Health Syst Pharm. 2012;69(6):483-486. © 2012 American Society of Health-System Pharmacists, Inc. Wendy M. Covert, Pharm.D., is Postgraduate Year 2 Oncology ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

Conclusion. Various agents evaluated for mucus control after urinary diversion procedures (oral ranitidine or aspirin, N-acetylcysteine or urea instillations, and subcutaneous octreotide), while ...